ChromaDex Corporation logo
ChromaDex Corporation CDXC

Quarterly report 2025-Q3
added 11-04-2025

report update icon

ChromaDex Corporation Financial Ratios 2011-2025 | CDXC

Annual Financial Ratios ChromaDex Corporation

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

50.4 -26.3 -7.1 -6.8 -13.6 -7.6 -5.4 -20.0 -51.7 -20.0 - -37.1 -4.9 -37.7

P/S

4.3 1.6 1.6 2.7 4.6 5.3 5.7 10.7 6.5 7.0 - 16.1 4.9 10.2

EPS

0.1 -0.1 -0.2 -0.4 -0.3 -0.6 -0.6 -0.3 -0.1 -0.1 - -0.0 -0.1 -0.1

EV (Enterprise Value)

408 M 129 M 123 M 181 M 276 M 246 M 171 M 191 M 155 M 111 M - 165 M 61.4 M 78.3 M

EBITDA per Share

0.11 -0.06 -0.25 -0.39 -0.321 -0.522 -0.588 -0.351 -0.0508 -0.14 - -0.124 -0.375 -0.102

EV/EBITDA

-5.1 -13.8 -7.6 -4.8 -11.7 -77.5 -21.3 - -39.3 -5.0 -45.8

PEG

-0.61 0.94 -11.15 -0.05 -0.36 -0.93 0.04 0.09 -1.05 1.38 - -0.56 0.64 1.09

P/B

9.3 4.6 4.1 5.8 16.5 12.0 6.6 4.2 27.1 26.9 - 28.9 14.3 15.6

P/CF

35.6 18.2 -7.8 -7.6 -25.2 -11.6 -8.0 -20.4 -51.9 -37.9 - -39.6 -5.6 -27.0

ROE %

18.55 -17.35 -57.69 -85.50 -121.32 -157.24 -122.58 -21.13 -52.54 -134.76 - -77.95 -292.23 -41.50

ROA %

12.52 -8.98 -30.60 -46.90 -51.94 -79.87 -78.89 -18.14 -14.78 -46.79 - -49.17 -129.13 -31.49

ROCE %

16.76 -19.68 -64.97 -85.33 -90.73 -124.29 -119.36 -29.97 -23.51 -80.04 - -71.38 -272.60 -37.62

Current Ratio

3.1 2.1 2.1 2.2 2.0 2.2 2.5 7.1 1.7 2.0 - 2.0 1.7 4.3

DSO

- - 13.2 14.1 16.6 17.1 51.1 91.9 40.6 45.4 - 37.7 61.0 48.2

DIO

113.9 162.5 176.4 177.8 177.8 205.2 194.2 197.3 220.5 136.5 - 114.2 203.6 112.2

DPO

90.1 110.8 125.4 139.7 143.7 171.2 224.8 126.6 167.9 126.1 - 74.8 134.0 40.3

Operating Cycle

113.9 162.5 189.7 191.9 194.4 222.3 245.3 289.2 261.1 181.9 - 151.9 264.6 160.4

Cash Conversion Cycle

23.8 51.7 64.2 52.2 50.7 51.1 20.5 162.6 93.2 55.8 - 77.2 130.6 120.1

All numbers in USD currency

Quarterly Financial Ratios ChromaDex Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.06 0.05 0.07 - 0.02 - -0.01 - -0.01 -0.03 -0.03 - -0.01 -0.09 -0.11 - -0.13 -0.08 -0.12 - -0.07 -0.06 -0.1 - -0.12 -0.14 -0.15 - -0.16 -0.15 -0.15 -0.17 0.05 -0.07 -0.05 -0.06 -0.03 - 0.01 -0.03 - -0.01 -0.03 - -0.01 -0.02 -0.02 -0.01 -0.01 -0.01 0.02 - -0.02 -0.04 -0.05 - -0.03 -0.03 -0.02

EBITDA per Share

- - 0.06 - - - -0.01 - - - -0.02 - -0.04 -0.09 -0.11 - -0.12 -0.08 -0.11 - -0.06 -0.05 -0.09 - -0.11 -123 -148 - -148 -140 -151 -0.17 -59.1 -0.06 -0.04 -0.06 -0.02 0.01 - -0.03 - - -0.02 - - -0.01 -0.02 -0.01 -0.01 -0.01 -0.01 - -0.01 -0.04 -0.05 - -0.03 -0.03 -0.01

ROE %

26.71 25.70 20.03 3.72 0.20 -8.77 -16.79 -18.37 -23.06 -24.23 -46.95 -65.38 -90.37 -110.66 -93.08 -55.03 -80.69 -81.37 -90.76 -84.19 -119.42 -128.98 -144.32 -113.93 -145.60 -142.03 -133.72 -92.35 -108.73 -73.10 -48.62 -21.14 -26.27 -39.81 -35.50 -29.36 -38.53 -29.05 -36.31 -66.67 -50.62 -65.19 -95.38 -91.47 -104.26 -111.68 -91.42 -78.01 -103.74 -120.19 -202.18 -249.51 -343.41 -398.79 -370.71 -210.98 -93.89 -71.94 -45.15

ROA %

18.16 16.81 12.84 2.39 0.59 -4.52 -8.62 -9.45 -11.61 -11.97 -21.58 -30.50 -45.15 -57.65 -52.38 -33.80 -44.79 -41.13 -42.35 -36.05 -53.94 -60.85 -70.44 -57.88 -78.25 -80.73 -80.53 -59.43 -73.49 -49.71 -35.06 -18.14 -14.94 -23.18 -19.19 -14.82 -14.61 -9.81 -11.60 -22.23 -19.16 -26.72 -43.12 -48.02 -56.08 -62.41 -55.15 -49.18 -58.14 -61.25 -94.10 -110.29 -148.64 -169.98 -155.16 -86.19 -38.36 -29.39 -18.44

ROCE %

24.24 22.91 17.11 1.30 -2.90 -11.76 -19.46 -19.75 -34.33 -44.71 -66.92 -75.20 -100.14 -110.50 -92.94 -54.92 -80.46 -81.07 -90.34 -83.86 -117.55 -125.69 -138.36 -109.76 -141.39 -139.32 -133.41 -91.74 -108.04 -82.31 -58.03 -30.42 -35.89 -39.26 -32.74 -29.13 -34.96 -21.61 -27.92 -52.81 -39.58 -58.04 -91.33 -90.74 -103.36 -110.90 -90.77 -77.42 -103.16 -119.59 -201.56 -249.01 -342.62 -397.88 -369.67 -210.07 -93.61 -71.64 -44.82

Current Ratio

3.6 3.4 3.1 3.1 2.5 2.3 2.1 2.1 2.0 2.0 2.1 2.1 1.9 1.8 2.0 2.2 2.4 2.8 2.7 1.8 1.8 1.8 1.8 2.0 2.0 2.0 2.0 2.8 2.8 2.8 2.8 7.1 7.1 7.1 7.1 2.0 2.0 2.0 2.0 1.5 1.4 1.4 1.5 - 2.1 1.9 2.3 2.7 2.7 2.7 2.7 1.8 - - - - - - -

DSO

24.4 24.5 22.2 - 26.6 28.9 24.4 - - - 35.8 - 24.0 28.7 30.5 - 29.8 15.5 8.4 - 17.3 18.7 18.2 - 44.3 45.4 43.9 - 49.0 51.0 67.4 - 80.1 115.5 - - - - - - - - - - - - - - - - - - - - - - 39.1 36.9 -

DIO

125.6 107.2 83.4 - 107.7 121.1 141.8 - 149.1 136.8 134.2 - 208.9 211.8 196.1 - 168.5 165.2 204.7 - 186.2 172.0 175.6 - 198.4 217.2 190.2 - 200.2 190.2 186.8 - 166.9 250.8 357.4 - 348.1 153.6 136.9 - 87.0 79.4 44.2 - 90.0 99.6 102.6 - 102.2 115.2 203.4 - 199.7 249.2 154.9 - 194.8 195.4 -

DPO

100.0 101.8 78.4 - 73.3 80.7 95.1 - 116.6 108.7 94.0 - 128.5 136.2 137.0 - 140.8 143.5 177.0 - 150.5 139.0 144.2 - 165.6 181.2 184.3 - 231.8 220.2 176.5 - 107.1 160.9 252.8 - 263.0 116.0 110.9 - 79.8 72.1 36.1 - 87.7 86.9 73.4 - 66.8 75.3 133.7 - 131.6 164.1 108.4 - 150.9 151.3 -

Operating Cycle

150.0 131.7 105.6 - 134.3 150.0 166.1 - 149.1 136.8 170.0 - 232.9 240.6 226.6 - 198.3 180.7 213.1 - 203.5 190.6 193.8 - 242.7 262.6 234.1 - 249.2 241.2 254.2 - 246.9 366.3 357.4 - 348.1 153.6 136.9 - 87.0 79.4 44.2 - 90.0 99.6 102.6 - 102.2 115.2 203.4 - 199.7 249.2 154.9 - 233.9 232.2 -

Cash Conversion Cycle

50.0 29.9 27.2 - 61.0 69.3 71.0 - 32.5 28.1 76.0 - 104.3 104.3 89.5 - 57.5 37.2 36.1 - 53.0 51.6 49.6 - 77.1 81.4 49.8 - 17.5 21.0 77.7 - 139.9 205.3 104.6 - 85.1 37.5 26.1 - 7.2 7.3 8.1 - 2.3 12.7 29.1 - 35.4 39.9 69.8 - 68.2 85.1 46.5 - 83.0 80.9 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company ChromaDex Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
AbbVie AbbVie
ABBV
$ 223.98 -0.53 % $ 396 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.67 1.74 % $ 775 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.36 2.75 % $ 260 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 210.16 4.43 % $ 5 B danmarkDanmark
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.33 -1.48 % $ 7.25 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.42 2.09 % $ 8.23 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.9 0.74 % $ 1.25 B usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 90.29 - $ 96.9 B britainBritain
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.49 - $ 139 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.28 - $ 14.3 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Biogen Biogen
BIIB
$ 172.5 - $ 25.1 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.96 1.17 % $ 533 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Axon Enterprise Axon Enterprise
AXON
$ 581.03 2.22 % $ 44 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.29 -0.31 % $ 631 M israelIsrael
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 15.31 - $ 1.01 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.15 13.76 % $ 397 M usaUSA
BioVie BioVie
BIVI
$ 1.51 -4.43 % $ 2.23 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.94 - $ 1.8 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.78 -5.97 % $ 46.2 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.44 7.92 % $ 740 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.0 - $ 27.2 B germanyGermany
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA